EGFR and lung adenocarcinoma: We also evaluated PFS and overall survival (OS) according to EGFR mutation type (exon 19 deletion and exon 21 L858R) because they constitute ~90% of all EGFR mutation-positive lung adenocarcinomas, and are strongly associated with robust responses to EGFR-TKIs [17, 18].